PURPOSE: Early-onset cancer (EOC), defined as cancer occurring in individuals age 15-49 years, represents a growing global health burden. This study aims to assess the epidemiologic trends of EOC from 1990 to 2021 and project future incidence and mortality trends up to 2040. MATERIALS AND METHODS: Using data from the Global Burden of Disease (GBD) 2021 study, we analyzed the age-specific incidence rate (AsIR) and death rate (AsDR) per 100,000 patient-years for 31 cancer types across 204 countries. Statistical modeling, including the two sample t test, was done to estimate the standard deviations among each group, which is plugged in the denominator to compute the statistic. Autoregressive integrated moving average and exponential smoothing state space were employed for forecasting future trends. RESULTS: In 2021, there were approximately 23.6 million new EOC cases and 0.99 million deaths globally. The highest AsIRs were observed in breast, nonmelanoma skin, and cervical cancers, with the highest AsDRs seen in breast and lung cancers in 2021. Although AsIR has increased globally, AsDR has declined from 1990 to 2021. EOC disproportionately affected women, particularly in high-income countries. Risk factor analysis highlights obesity, tobacco use, and dietary patterns as key contributors to EOC burden. Projected analysis till 2040 revealed relatively stable AsIR and declining AsDR for overall EOCs. CONCLUSION: The increasing global burden of EOC underscores the need for targeted strategies. Regional disparities highlight the importance of health care access in mitigating EOC mortality. Healthy lifestyle could reduce the burden of EOC.
T -cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is a rare and aggressive leukemia. Philadelphia chromosome -positive cytogenetic abnormality is most common in CML. It is difficult to differentiate between de novo Ph + T-ALL/LBL and T-cell lymphoblastic crises of CML. We present a case of adult Ph + T-ALL/LBL with a likely history of antecedent CML. Initially thought to be a case of chronic -phase CML, a diagnostic quandary led to the pursuit of a lymph node biopsy that established the diagnosis of Ph + T-LBL or T lymphoblastic blast crisis of CML, a clinical presentation extremely rare and only the second of its kind from our review of the literature. The patient was treated with an intensive chemotherapy regimen for over a year due to persistent minimal residual disease (MRD) positivity indicating aggressive disease.
Lactic acidosis, characterised by an imbalance between lactate production and clearance, is classified into type A and type B. Type A is associated with tissue hypoxia and shock, while type B occurs without hypoxia, often due to metabolic disturbances, such as cancer-related metabolic reprogramming, known as the Warburg effect. This case series presents two patients with undiagnosed B-cell lymphoma who exhibited distinct forms of lactic acidosis. The first patient, with septic shock and end-organ hypoperfusion, developed type A lactic acidosis, with escalating lactate levels despite aggressive resuscitation. The second patient, with stable haemodynamics but persistently elevated lactate, exhibited type B lactic acidosis, likely due to the Warburg effect of lymphoma. These cases underscore the importance of differentiating between type A and type B lactic acidosis, as the underlying aetiology guides treatment strategies. Early recognition of the cause is crucial for optimal management and patient outcomes, particularly in malignancy-associated metabolic disturbances.
Semaglutide, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, is widely used for type 2 diabetes mellitus and has demonstrated hepatoprotective effects. However, this case highlights a rare instance of possible drug‐induced liver injury (DILI) temporally linked to its use. A middle‐aged male with well‐controlled diabetes, social alcohol use, and no history of liver disease presented with asymptomatic elevations in alanine transaminase (ALT) and aspartate aminotransferase (AST). Extensive workup, including undetectable blood ethanol level, normal viral hepatitis panel, and unremarkable liver ultrasound, revealed no alternative etiology. Given the temporal association and absence of other factors, semaglutide was suspected as the culprit, leading to its discontinuation. A rapid decline in transaminase levels upon withdrawal supported this diagnosis. Although semaglutide is primarily metabolized through proteolytic cleavage and beta‐oxidation with minimal hepatic involvement, this case suggests the possibility of idiosyncratic liver injury. The mechanism remains unclear but may involve metabolic stress, weight loss, or biliary dysfunction. With the increasing use of semaglutide, clinicians should maintain a high index of suspicion for unexplained liver enzyme elevations, particularly following dose adjustments.
Introduction: Colorectal cancer (CRC) ranks third among cancers globally, posing a significant public health issue. This study aimed to analyze CRC incidence, mortality, and risk factors across India from 1990 to 2021 using data from the Global Burden of Disease (GBD) 2021 study. Methods: We utilized GBD 2021 data, analyzing age‐standardized incidence rates (ASIR), age‐standardized death rates (ASDR), and annual percentage changes (APC) for CRC across India's 31 states. Statistical modeling, including two sample t ‐tests, was done. Results: In 2021, India reported 69,409 CRC cases (ASIR: 5.69 per 100,000) and 54,018 deaths (ASDR: 4.60 per 100,000). Both ASIR and ASDR showed increases from 1990 to 2021, highest in adults aged 85+, although these trends were not statistically significant. Mizoram reported the highest incidence rate. Behavioral risks accounted for the largest proportion of CRC deaths (38.85% [95% UI: 24.71–50.32]), particularly diets low in milk (19.16% [95% UI: 5.28–30.72]). High BMI contributed to 4.17% of CRC deaths and showed the highest increase from 1990 to 2021 (+127.47%). Conclusion: The rising incidence and mortality of CRC in India highlight the need for targeted public health interventions emphasizing dietary changes, improved screening, and healthcare infrastructure.